Elypta launches Multi-Cancer Early Detection screening study measuring metabolic GAGome levels in asymptomatic adults
Stockholm, Feb 15, 2022: Swedish molecular diagnostic company Elypta announces today the launch of clinical study LEVANTIS-0087A (LEV87A), intended to validate the diagnostic performance of GAGomes – the complete profile of human glycosaminoglycans – as metabolic biomarkers for Multi-Cancer Early Detection (MCED). The study aims to detect any-type cancer in adults who show no symptoms or have any recent history of cancer. The study builds upon proof-of-concept data shared at the American Society of Clinical Oncology (ASCO) conference in June 2021 which indicated that GAGomes could detect one